Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

The economics of bladder cancer: costs and considerations of caring for this disease.

Svatek RS, Hollenbeck BK, HolmÀng S, Lee R, Kim SP, Stenzl A, Lotan Y.

Eur Urol. 2014 Aug;66(2):253-62. doi: 10.1016/j.eururo.2014.01.006. Epub 2014 Jan 21. Review.

PMID:
24472711
2.

Cost-effective treatment of low-risk carcinoma not invading bladder muscle.

Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK.

BJU Int. 2013 Mar;111(3 Pt B):E78-84. doi: 10.1111/j.1464-410X.2012.11454.x. Epub 2012 Sep 7.

3.

[Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].

RouprĂȘt M, Malavaud B, Molinier L, Leleu H, Blachier M, Marteau F.

Prog Urol. 2015 Apr;25(5):256-64. doi: 10.1016/j.purol.2015.01.004. Epub 2015 Jan 17. French.

PMID:
25605343
4.
5.

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.

Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D.

Eur Urol. 2014 Nov;66(5):863-71. doi: 10.1016/j.eururo.2014.06.037. Epub 2014 Jul 4. Review.

PMID:
25001887
6.

The health economics of bladder cancer: a comprehensive review of the published literature.

Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R.

Pharmacoeconomics. 2003;21(18):1315-30. Review.

PMID:
14750899
7.

Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.

Coblentz TR, Mills SE, Theodorescu D.

Cancer. 2001 Apr 1;91(7):1284-90.

PMID:
11283928
8.

The health economics of bladder cancer: an updated review of the published literature.

Yeung C, Dinh T, Lee J.

Pharmacoeconomics. 2014 Nov;32(11):1093-104. doi: 10.1007/s40273-014-0194-2. Review.

PMID:
25056838
10.

Economic impact of tumor markers in bladder cancer surveillance.

Hong YM, Loughlin KR.

Urology. 2008 Jan;71(1):131-5. doi: 10.1016/j.urology.2007.08.014. Review.

PMID:
18242381
11.

The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.

Richards KA, Smith ND, Steinberg GD.

J Urol. 2014 Jun;191(6):1655-64. doi: 10.1016/j.juro.2014.01.087. Epub 2014 Feb 8. Review.

PMID:
24518761
12.

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, Stepp H, Zaak D, Witjes JA.

Eur Urol. 2013 Oct;64(4):624-38. doi: 10.1016/j.eururo.2013.07.007. Epub 2013 Jul 19. Review.

PMID:
23906669
13.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
14.

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU.

Urology. 2001 Sep;58(3):380-5.

PMID:
11549485
15.

Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.

Einstein AB Jr, Wolf M, Halliday KR, Miller GJ, Hafermann M, Lowe BA, Meyers FJ, Leimert JT, Crawford ED.

Urology. 1996 May;47(5):652-7.

PMID:
8650861
16.

Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.

Feifer A, Xie X, Brophy JM, Segal R, Kassouf W.

Urology. 2010 Sep;76(3):652-6. doi: 10.1016/j.urology.2009.12.070. Epub 2010 Apr 15.

PMID:
20394970
17.

Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.

Maarouf AM, Khalil S, Salem EA, ElAdl M, Nawar N, Zaiton F.

BJU Int. 2011 May;107(10):1605-10. doi: 10.1111/j.1464-410X.2010.09564.x. Epub 2010 Sep 3.

18.

Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

Prout GR Jr, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Bassil B, Nocks BN, Parkhurst EC, Young HH 2nd.

J Urol. 1990 Nov;144(5):1128-34; discussion 1134-6.

PMID:
2122007
19.

Surgical advances in bladder cancer: at what cost?

Johnson DC, Greene PS, Nielsen ME.

Urol Clin North Am. 2015 May;42(2):235-52, ix. doi: 10.1016/j.ucl.2015.01.005. Epub 2015 Mar 3. Review.

PMID:
25882565
20.

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.

Shelley M, Cleves A, Wilt TJ, Mason M.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. Review.

PMID:
21491413
Items per page

Supplemental Content

Write to the Help Desk